<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In our previous study, approximately 60% of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> (RA) patients treated with recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human erythropoietin (rhEpo) showed a multilineage response </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we analyzed the long-term follow-up of the multilineage responders (multi-R) </plain></SENT>
<SENT sid="2" pm="."><plain>In the follow-up analysis of 11 multi-R (6 AA and 5 RA), 10 patients (5 AA and 5 RA) were evaluable </plain></SENT>
<SENT sid="3" pm="."><plain>The range of time from the start of treatment to the final contact was 50 to 125 months </plain></SENT>
<SENT sid="4" pm="."><plain>Analysis of survival times revealed a significant difference between multi-R and non-multi-R among AA patients given this treatment (P = .016) </plain></SENT>
<SENT sid="5" pm="."><plain>One AA and 1 RA patient among the multi-R developed <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Of 7 living multi-R, 3 AA and 2 RA patients did not need transfusion at final contact </plain></SENT>
<SENT sid="7" pm="."><plain>Four of them maintained the target <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> concentration of more than 11 g/dL for quality-of-life benefit </plain></SENT>
<SENT sid="8" pm="."><plain>The findings suggested that this result is an important advantage of this treatment </plain></SENT>
</text></document>